Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PTN |
---|---|---|
09:32 ET | 12928 | 1.65 |
09:38 ET | 100 | 1.658 |
09:41 ET | 7867 | 1.6768 |
09:43 ET | 5100 | 1.61 |
09:48 ET | 461 | 1.65 |
09:52 ET | 5980 | 1.65 |
09:57 ET | 5211 | 1.65 |
09:59 ET | 6780 | 1.65 |
10:03 ET | 100 | 1.66 |
10:12 ET | 500 | 1.6538 |
10:15 ET | 450 | 1.65 |
10:17 ET | 9281 | 1.65 |
10:21 ET | 342 | 1.665 |
10:30 ET | 100 | 1.67 |
10:32 ET | 100 | 1.67 |
10:33 ET | 300 | 1.66 |
10:35 ET | 600 | 1.6601 |
10:44 ET | 109 | 1.6739 |
10:46 ET | 200 | 1.6675 |
10:51 ET | 322 | 1.6701 |
10:53 ET | 34652 | 1.73 |
10:55 ET | 200 | 1.73 |
10:57 ET | 3000 | 1.7 |
11:02 ET | 105 | 1.6819 |
11:04 ET | 5100 | 1.69 |
11:08 ET | 1348 | 1.72 |
11:09 ET | 14760 | 1.72 |
11:11 ET | 2582 | 1.7203 |
11:13 ET | 1000 | 1.7386 |
11:15 ET | 100 | 1.74 |
11:18 ET | 10567 | 1.77 |
11:20 ET | 1200 | 1.77 |
11:22 ET | 3999 | 1.7501 |
11:24 ET | 1498 | 1.76 |
11:29 ET | 1503 | 1.7778 |
11:31 ET | 630 | 1.77 |
11:36 ET | 3704 | 1.78 |
11:38 ET | 383 | 1.7997 |
11:40 ET | 4933 | 1.81 |
11:42 ET | 490 | 1.8 |
11:44 ET | 5092 | 1.8199 |
11:45 ET | 280 | 1.82 |
11:47 ET | 564 | 1.8281 |
11:49 ET | 1689 | 1.84 |
11:51 ET | 5250 | 1.84 |
11:54 ET | 2087 | 1.8599 |
11:56 ET | 1700 | 1.8512 |
11:58 ET | 19450 | 1.89 |
12:00 ET | 4993 | 1.9 |
12:02 ET | 2092 | 1.91 |
12:03 ET | 6150 | 1.92 |
12:05 ET | 1200 | 1.9 |
12:07 ET | 1400 | 1.8747 |
12:09 ET | 627 | 1.8707 |
12:16 ET | 1250 | 1.88 |
12:18 ET | 1450 | 1.9 |
12:20 ET | 300 | 1.88 |
12:21 ET | 358 | 1.87 |
12:23 ET | 500 | 1.866 |
12:25 ET | 380 | 1.86 |
12:30 ET | 3158 | 1.85 |
12:34 ET | 3000 | 1.8508 |
12:36 ET | 1303 | 1.8357 |
12:38 ET | 850 | 1.83 |
12:39 ET | 600 | 1.84 |
12:41 ET | 300 | 1.84 |
12:45 ET | 373 | 1.84 |
12:52 ET | 100 | 1.8491 |
12:54 ET | 1200 | 1.8469 |
12:56 ET | 550 | 1.84 |
01:01 ET | 100 | 1.84 |
01:03 ET | 800 | 1.85 |
01:06 ET | 145 | 1.8301 |
01:10 ET | 3700 | 1.86 |
01:12 ET | 550 | 1.86 |
01:14 ET | 1000 | 1.86 |
01:15 ET | 1160 | 1.855 |
01:17 ET | 146 | 1.8554 |
01:19 ET | 809 | 1.85 |
01:21 ET | 134 | 1.841 |
01:30 ET | 512 | 1.8501 |
01:33 ET | 400 | 1.85 |
01:35 ET | 1000 | 1.859 |
01:42 ET | 1417 | 1.84 |
01:46 ET | 5437 | 1.86 |
01:51 ET | 2340 | 1.8768 |
01:53 ET | 10901 | 1.84 |
01:55 ET | 653 | 1.87 |
02:02 ET | 200 | 1.87 |
02:08 ET | 951 | 1.845 |
02:09 ET | 10883 | 1.83 |
02:11 ET | 3700 | 1.82 |
02:13 ET | 200 | 1.82 |
02:22 ET | 165 | 1.812 |
02:26 ET | 200 | 1.82 |
02:38 ET | 100 | 1.81 |
02:40 ET | 814 | 1.82 |
02:42 ET | 900 | 1.79 |
02:44 ET | 1127 | 1.8 |
02:45 ET | 200 | 1.8 |
02:51 ET | 600 | 1.8 |
03:02 ET | 100 | 1.8099 |
03:03 ET | 600 | 1.8 |
03:05 ET | 490 | 1.805 |
03:20 ET | 5200 | 1.81 |
03:21 ET | 1445 | 1.82 |
03:23 ET | 10387 | 1.8399 |
03:30 ET | 400 | 1.825 |
03:34 ET | 100 | 1.82 |
03:36 ET | 107 | 1.83 |
03:39 ET | 1095 | 1.83 |
03:41 ET | 1190 | 1.83 |
03:45 ET | 961 | 1.825 |
03:48 ET | 2305 | 1.84 |
03:50 ET | 1900 | 1.8298 |
03:56 ET | 1019 | 1.82 |
03:57 ET | 4093 | 1.85 |
03:59 ET | 23846 | 1.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Palatin Technologies Inc | 25.8M | -0.8x | --- |
Talis Biomedical Corp | 16.2M | -0.2x | --- |
Lipocine Inc | 27.3M | -1.7x | --- |
Synlogic Inc | 20.7M | -0.2x | --- |
Alaunos Therapeutics Inc | 29.8M | -0.8x | --- |
Evogene Ltd | 37.2M | -1.4x | --- |
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.8M |
---|---|
Revenue (TTM) | $7.1M |
Shares Outstanding | 16.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-2.48 |
Book Value | $0.01 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 3.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -324.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.